company background image
532321 logo

Zydus Lifesciences BSE:532321 Stock Report

Last Price

₹1.02k

Market Cap

₹1.0t

7D

5.0%

1Y

110.2%

Updated

26 Mar, 2024

Data

Company Financials +

Zydus Lifesciences Limited

BSE:532321 Stock Report

Market Cap: ₹1.0t

532321 Stock Overview

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally.

532321 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends4/6

Zydus Lifesciences Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zydus Lifesciences
Historical stock prices
Current Share Price₹1,018.10
52 Week High₹1,028.45
52 Week Low₹478.45
Beta0.54
1 Month Change10.41%
3 Month Change47.85%
1 Year Change110.18%
3 Year Change134.50%
5 Year Change195.70%
Change since IPO15,725.57%

Recent News & Updates

Recent updates

Shareholder Returns

532321IN PharmaceuticalsIN Market
7D5.0%2.4%2.3%
1Y110.2%65.0%48.6%

Return vs Industry: 532321 exceeded the Indian Pharmaceuticals industry which returned 65% over the past year.

Return vs Market: 532321 exceeded the Indian Market which returned 47.6% over the past year.

Price Volatility

Is 532321's price volatile compared to industry and market?
532321 volatility
532321 Average Weekly Movement3.6%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.6%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.0%

Stable Share Price: 532321's share price has been volatile over the past 3 months.

Volatility Over Time: 532321's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
195223,026Sharvil Patelhttps://www.zyduslife.com

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases.

Zydus Lifesciences Limited Fundamentals Summary

How do Zydus Lifesciences's earnings and revenue compare to its market cap?
532321 fundamental statistics
Market cap₹1.02t
Earnings (TTM)₹29.56b
Revenue (TTM)₹190.24b

34.6x

P/E Ratio

5.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
532321 income statement (TTM)
Revenue₹190.24b
Cost of Revenue₹64.73b
Gross Profit₹125.51b
Other Expenses₹95.95b
Earnings₹29.56b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 30, 2024

Earnings per share (EPS)29.38
Gross Margin65.97%
Net Profit Margin15.54%
Debt/Equity Ratio0.9%

How did 532321 perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

24%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.